We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.
Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease
What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.
Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.
Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.
A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.
Possible benefits and risks:
Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.
NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.
Researchers will monitor participants closely for any side effects throughout the study.

Start Date01 Apr 2025

Sponsor / Collaborator

Metro International Biotech LLC

NCT05083546

/ Not yet recruitingPhase 1/2IIT

Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging

Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of California, San Francisco

NCT06488625

/ RecruitingPhase 2/3IIT

A Phase II/III, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) for Induction and Maintenance Therapy in Patients with Mild to Moderately Active Ulcerative Colitis

Double-blind, randomised, placebo-controlled phase II / III trial evaluating efficacy and safety of two different doses (2 g/d or 3 g/d) of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to placebo in patients with ulcerative colitis (UC).
The intended therapeutic use of CICR-NAM is to improve intestinal inflammation in adults with UC by topically increasing nicotinamide supply in the ileocolonic region and thus favourably influencing the composition of intestinal microbiota

Start Date12 Sep 2024

Sponsor / Collaborator

Universitätsklinikum Schleswig-Holstein Campus Kiel

[+3]

100 Clinical Results associated with Nicotinamide

100 Translational Medicine associated with Nicotinamide

100 Patents (Medical) associated with Nicotinamide

19,780

Literatures (Medical) associated with Nicotinamide

01 Dec 2025·Molecular Biology Reports

Do human adipose stem cell-derived artificial insulin-producing cells develop tumorigenic characteristics throughout differentiation?

Article

Author: Forouzanfar, Mohsen ; Jafarinia, Mojtaba ; Salehi Babadi, Parastoo ; Dayer, Dian

BACKGROUNDArtificial insulin-producing cells (IPCs) used to treat diabetes mellitus type 1 (DMT1) are naturally hampered by their carcinogenicity. This in vitro study aimed to examine the carcinogenic potential of IPCs produced by the differentiation of human adipose tissue-derived mesenchymal stem cells (hADSCs).METHODS AND RESULTShADSCs were transformed into IPCs by administering insulin-transferrin, selenium (ITS), and nicotinamide in a 14-day differentiation protocol. The cells were transfected with 20 μg of pure Pdx1-pIRES recombinant vector on the tenth day of differentiation. The successful transfection was confirmed by Pdx1 overexpression and GFP fluorescence activity. The differentiated cells' capacity to release insulin and glucose-dependent C-peptide was used to evaluate their functionality. Gene expression was assessed using real-time PCR. Meanwhile, protein expression was investigated using western blotting. The transfected cells exhibited fluorescence activity and Pdx1 overexpression. The differentiated IPCs were able to secrete C-peptide and insulin. The artificial IPCs showed significantly reduced Oct4 and Nanog expression. However, the differentiation process induced a noticeable elevation in tPA expression. The artificial IPCs expressed much lower c-MYC expression compared to undifferentiated hADSCs. The differentiated cells exhibited a significant elevation in Glut2, MMP-2, CD24, P16, and P21 expression.CONCLUSIONSThe differentiation technique used in this work produced functional beta-like cells devoid of typical markers of stem cells. The synthetic IPCs displayed characteristics of newly generated β-like cells. The artificial IPCs showed no signs of expressing tumor-associated markers. The findings imply that the artificial IPC cells lack tumor characteristics in vitro.

01 Sep 2025·Comparative Biochemistry and Physiology Part D: Genomics and Proteomics

Dynamic metabolic profiling of sea cucumbers (Apostichopus japonicus) under predation stress

Article

Author: Song, Jian ; Wang, Shuo ; Wang, Qingzhi ; Qu, Liang ; Sun, Yongxin ; Wang, Meng ; Zhao, Chong ; Wang, Chong

The present study utilized non-targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) to investigate the metabolomic responses of sea cucumber (Apostichopus japonicus) juveniles under predation stress induced by sea stars (Asterina pectinifera) at various time points (3 h, 12 h, 72 h, and 96 h). The findings revealed significant temporal changes in the metabolic profiles of the sea cucumber juveniles under predation stress, with 25, 72, 55, and 53 metabolic products exhibiting significantly different expression levels at each time point (positive ion mode, P < 0.05), respectively. Notably, the impact of predation stress was most pronounced at the 12-h mark. Multivariate statistical methods, including principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA), further confirmed distinct clustering of the experimental group away from the control group at each time point, with the most pronounced separation occurring at 12 h, indicating a significant and time-dependent metabolic response to predation stress. Key metabolic pathways associated with predation stress were identified, such as carbon metabolism, pentose phosphate pathway, purine metabolism, riboflavin metabolism, longevity regulation, and antifolate resistance pathways, by integrating variable importance in the projection (VIP), fold change (FC), and P-value. KEGG enrichment analysis highlighted significant expression changes of key metabolites like carbamoyl phosphate, gluconolactone, inosine, 2'-deoxyguanosine, and adenylate in response to predation stress, potentially related to energy metabolism, antioxidant defense, signal transduction, and cellular stress responses. The study provides novel insights into the metabolic adaptability of sea cucumber juveniles to predation stress.

01 Aug 2025·Tissue and Cell

Melatonin promotes diabetic wound healing by mediating mitochondrial function in endothelial cells through the AMPK/SIRT1/HIF-1α pathway

Article

Author: Gao, Lei ; Wang, Jiangning ; Li, Tianbo ; Yu, Zeyang

OBJECTIVEDiabetic wounds are open lesions that can develop on any part of the body of diabetic patients. Importantly, melatonin (Mel) exerts promotional effects on wound healing. Accordingly, this study explored the mechanism of Mel in diabetic wound healing by mediating mitochondrial function in endothelial cells.METHODSHuman umbilical vein vascular endothelial cells (HUVECs) were exposed to high glucose (HG) to mimic a diabetic environment in vitro, followed by Mel treatment. Cell viability, invasion and angiogenic capacity were evaluated with CCK-8, Transwell, and tube formation assays, respectively. CD31 protein expression was determined with Western blot. Wound healing ability was evaluated in vitro, and the levels of adenosine triphosphate (ATP), reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and apoptosis-related proteins (Bcl-2/Bax/CytC) were also detected. To verify the role of the AMPK/SIRT1/HIF-1α pathway in diabetic wound healing, HG-induced HUVECs treated with Mel were subjected to treatment with sh-HIF-1α, AMPK inhibitor (compound c), or SIRT1 inhibitor (Nicotinamide).RESULTSHG impaired the proliferation, invasion, angiogenesis, and wound healing ability of HUVEC, increased ROS, Bax, and CytC levels, and decreased MMP and the levels of ATP and Bcl-2. Mel facilitated viability, angiogenesis, and wound healing ability while ameliorating mitochondrial dysfunction in HG-treated HUVECs. Mel activated the AMPK/SIRT1 pathway to upregulate HIF-1α in HG-treated HUVECs. HIF-1α knockdown, CC, or Nicotinamide negated the effect of Mel on HG-treated HUVECs.CONCLUSIONSMel fosters angiogenesis and represses mitochondrial dysfunction in endothelial cells by activating the AMPK/SIRT1/HIF-1α pathway, thereby promoting diabetic wound healing.

News (Medical) associated with Nicotinamide

26 Mar 2025

·heidelberg-pharma.com

PR: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025

Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and advancement for its Exatecan-based ADC technology platform at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA, from 25 to 30 April. In addition to its proprietary Amanitin-based ADC technology, Heidelberg Pharma has developed a diverse ADC toolbox designed to overcome tumor resistance through multiple mechanisms, enabling targeted treatment across various cancer types. Dr. Sarah-Jane Neuberth will present preclinical findings on HDP-201, Heidelberg Pharma´s novel Exatecan-based, multimeric linker ADC, called ETAC technology, which is being developed for the treatment of colorectal cancer. The findings indicate target-specific potency, strong anti-tumor efficacy, and high tolerability. Dr. Pablo Ruedas Batuecas will demonstrate the potential of computational modeling for optimizing NAMPT inhibitors (NAMPTi) designed in silico as payloads and as a mode of action (MOA) in ADC technology. This novel technology approach has the potential to overcome the current limitations of cancer therapies by targeting both dividing and non-dividing cancer cells. AACR Annual Meeting 2025 Details of the conference and presentations are as follow: Poster: HDP-201 – a novel multimeric linker exatecan-based ADC targeting Guanylyl cyclase C (GCC) for treatment of gastrointestinal malignancies Abstract number: 1558 Session: Antibody-Based Cancer Therapeutics 1 Presentation time: 28 April, 9:00 am – 12:00 pm CST Speaker: Dr. Sarah-Jane Neuberth, Associate Director In Vivo Biology Link to abstract: https://www.abstractsonline.com/pp8/#!/20273/presentation/2830 The ETAC HDP-201 is directed against the surface protein GCC (guanylyl cyclase C), which is highly overexpressed in gastrointestinal malignancies, including gastric and colorectal cancers. HDP-201 showed potent anti-tumor efficacy in preclinical models, including complete tumor remission of GCC-expressing CDX models and significant inhibition of tumor growth in gastrointestinal PDX models. A single intravenous dose of 60 mg/kg of HDP-201 was well tolerated in cynomolgus monkeys, with no severe toxicity. These findings underscore the potential of HDP-201 as a promising new therapeutic option for GCC-positive gastrointestinal malignancies. Talk (Minisymposium): In silico optimized NAMPT inhibitor for targeted delivery by ADC as novel therapeutic modality for treatment of liquid and solid malignancies Abstract number: 1162 Stream: Antibody-Based Cancer Therapeutic Agents Presentation time: 27 April, 3:00 – 5:00 pm CST Speaker: Dr. Pablo Ruedas Batuecas, Scientist Chemistry Link to abstract: https://www.abstractsonline.com/pp8/#!/20273/presentation/2815 Nearly half of the US Food and Drug Administration (FDA) approved ADCs are based on microtubule inhibitors, that selectively target dividing cancer cells but fail to eradicate non-dividing tumor stem cells, potentially leading to resistance and tumor relapse. Inhibition of NAMPT, the rate-limiting enzyme in the salvage biosynthetic pathway of NAD+ starting from nicotinamide, induces cell death due to energy shortage in both dividing and non-dividing cell populations. This is a promising approach to overcome current therapy limitations by utilizing novel payloads. ADCs based on in silico designed NAMPTi as payloads show promising in vitro and in vivo results, highlighting the potential of NAMPT inhibition as an emerging MOA in ADC technology that enhances the targeted drug delivery to different cell lines.

AACRADC

28 Jan 2025

·www.prnewswire.com

Debut Unveils AI-powered Ingredient Discovery Platform to Fuel Biotech Innovation for All Beauty Brands Globally through Partner KDC/one

New discovery engine, BeautyORB™ by Debut, will create two novel, peak-performing biotech ingredients each year, giving beauty brands access to game-changing clinical claims and product innovation. Debut's new partnership with contract manufacturer KDC/one enables brands of all sizes to harness the power of biotech. SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Debut, the biotech beauty leader, announced today the launch of BeautyORB™, an AI-powered innovation engine that provides a new way to discover novel ingredients for best-in-class claims for beauty brands, from a typical time horizon of several years to two Debut ingredients launched each year. The genomics-based AI platform, which is on par with pharmaceutical-grade technology, has already fueled the creation of groundbreaking ingredients addressing inflammaging, epidermal barrier repair and longevity, with brightening, anti-aging and scalp care ingredients already in the pipeline. Continue Reading Image Credit: Billy Economou, BE Studios "With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction. This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims," said Joshua Britton, Ph.D, Founder and CEO of Debut. "We don't have to rely on an array of existing ingredients to test against specific claims, and we don't have to go into the field to find rare ingredients in plants. All this can be done at the click of a button, cutting out years from the innovation cycle and accessing ingredients that no one has seen before. We can turn on and off molecular pathways differently and use AI to discover what molecules can affect those pathways. The result is a rich, proven and growing pipeline of novel ingredients with the strongest clinical results for our customers, allowing brands to win on product performance rather than marketing". BeautyORB™ discovers new ingredients by screening 50 billion molecules for their ability to turn on cellular pathways within skin, a process that has never previously been possible in beauty. Debut's AI platform has already identified three novel, patented ingredients that achieve the highest beauty standards including scientifically-proven, clinically-tested and 100% bio-based ingredients that beat existing benchmarks. These ingredients include: DermCeutical InflammagePRO™: Best-in-class for inflammaging. Decreases inflammatory markers, supports the skin barrier and enhances elasticity. 15X better than niacinamide. DermCeutical Barrier RepairPRO™: Best-in-class for epidermal barrier repair. Defends the skin against damage from environmental aggressors. 30% better than vitamin C for skin damage repair. DermCeutical LongevityPRO™: Best-in-class for cellular longevity. Decreases markers of cellular senescence and helps maintain healthy skin cells. 2X better than vitamin C for skin health. "With BeautyORB™, we can develop ingredients that have the targeted responses we seek, using the same technology to find ingredients that fight disease. Our tool is another key step in the convergence of pharma and beauty. We are thrilled to partner with the industry leading contract manufacturer KDC/one to create finished products of the highest quality, in tandem with Debut's custom formulation business, BiotechXBeautyLabs™, to achieve our mission of reinventing product performance with the safest sustainability credentials. Our KDC/one partnership sets the stage for a global biomanufacturing revolution in beauty," said Britton. BeautyORB™ is the latest tool to emerge from Debut's ongoing commitment to lead the beauty industry's shift to biotech, creating a community of future-forward brands and product innovators that solve existing and emerging consumer needs. Using generative AI, BeautyORB™ delivers: More than 50 billion molecule possibilities 30,000 genes tested per molecule using omics technology 25,000 genes tested per second 21,000 molecules screened in silico per second for deep learning 200+ new biological pathways tested per molecule Over 60 million data points, with 100 million over the next 12 months About Debut The leader in biotech beauty Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance. About KDC/one Industry leading Contract Manufacturer KDC/one's Beauty & Personal Care manufacturing platform includes state-of-the-art facilities across North America, Europe, and Asia, allowing us to seamlessly deliver solutions for the complex production requirements of our global customers. With a global network of manufacturing, R&D, innovation hubs, and showrooms, KDC/one has end-to-end capabilities across formulation, design, packaging, and manufacturing to service a wide range of customer types, from start-up brands to multinational consumer companies. SOURCE Debut Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

11 Dec 2024

·www.prnewswire.com

Elume Offers Fuss-Free Skincare Solutions for All Skin Tones

The Indian Skincare Brand Is Empowering Women Around the World With Simple, Pleasant, Effective Skincare Solutions FORT LAUDERDALE, Fla., Dec. 11, 2024 /PRNewswire/ -- Elume is a forward-thinking skincare company that is empowering women through simple, streamlined, and effective skincare solutions for all skin tones. The breakout Indian brand's inclusive emphasis comes from its focus on its Asian-first philosophy and its desire to meet the unique needs of the Asian consumer. Elume has created its popular and diverse skincare range through a combination of simple choices and thorough education. The company focuses on reducing overwhelm through easily accessible information and positive experiences. "Our goal is to create pleasant, fuss-free experiences for everyone, no matter their skin tone or skincare needs," said Elume co-founder Pavneet. "Élume is more than a skincare brand; it's a celebration of diversity and natural beauty. Our products, enriched with potent ingredients like Vitamin C and Niacinamide, are crafted to meet the unique needs of people with melanated skin, ensuring they receive the care and nourishment their skin deserves." As a way to make the skincare journey easier, Elume has put a heavy emphasis on transparency throughout its business activity. Formulas are easy to find and presented in concise yet comprehensive formats. This makes it easier for customers to make the best choice based on their unique skin needs. In addition, the company has an entire page devoted to ingredient descriptions to further promote education and wise purchase decisions. There is also a clear dual focus on prevention and treatment. Some products help maintain healthy skin, while others address specific concerns and conditions. One of the best examples of Elume's comprehensive and effective approach to global skincare is its Vitamin C+ range. The popular product line includes a cleanser, toner, serum, and moisturizer, all with clear descriptions and applications. The collection is celebrated for brightening and revitalizing the skin and the ability to consistently deliver exceptional results based on clearly communicated expectations. The brand has similar products formulated for skin radiance, acne, hyperpigmentation, and aging skin. Elume is more than a skincare brand. On the surface, its products offer a proactive approach to skincare, ensuring long-term skin wellness and vitality. But it goes further. The company is also committed to exceptional service as it cares for consumers and gives them the confidence to care for their bodies without the need to cover up or alter them. About Elume Elume is a brand from Skin Habits Pvt. Ltd. and was launched in 2021 in the heart of North India, Chandigarh. The company operates with family values and an emphasis on a better tomorrow. This primarily focuses on leaving behind old, harmful ideologies that have resonated for generations. The Elume team has over 20 years of expertise in skincare and embraces an Asian-first philosophy founded on meticulous research in the areas of melanated skin, tropical weather, and a fast-paced lifestyle. Its products are dermatologically tested, PETA-approved cruelty-free, and manufactured at a WHO GMP-certified factory. Learn more at elume.in. Arvin Mondal Director, International Business Development M: +91 991 590 0348 E: [email protected] SOURCE Elume WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Nicotinamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00036	Nicotinamide	A11HA01	DB02701

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Coronary Artery Disease	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Myocarditis	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Vitamin B Deficiency	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Pellagra	Japan	Catalent Japan KK	27 Oct 1961
Acne Vulgaris	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Discovery	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010
Hyperphosphatemia	Discovery	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02416739 (Pubmed) Manual	Phase 2	EGFR Mutation Lung Cancer	110	Nicotinamide	(njtklofogm) = dsaqgiczck hkysptcnfy (kfpyzxoijl, 10.4 - 18.3) View more	Positive	09 Apr 2024
				Placebo	(njtklofogm) = nplglzqwff hkysptcnfy (kfpyzxoijl, 9.0 - 13.2) View more
NCT02416739 (AACR2024) Manual	Phase 2	EGFR Mutation Lung Cancer	110	Nicotinamide	(rrtfqrucoa) = xmafdjvvgj jpimxuqxmh (xicmjtrhtg, 10.4 - 18.3) View more	Positive	05 Apr 2024
				Placebo	(rrtfqrucoa) = tjrueanvcd jpimxuqxmh (xicmjtrhtg, 9.0 - 13.2) View more
NCT03136705 (CTgov)	Phase 1	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	tqdrqnrpay(mgezqzoubf) = hzxauzvqzx xveebuiyef (zfotssgfov, ffnovmvepe - iqxkvfjapm) View more	-	23 Feb 2024
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	tqdrqnrpay(mgezqzoubf) = ndeqnoyfum xveebuiyef (zfotssgfov, fhlvcmamli - wallzdgbev) View more
NCT03061474 (NEAT, CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	46	Nicotinamide (Nicotinamide)	bkljgotiha(unobfyednr) = grjqmtrqev kkzuiknapr (dgdcheawpk, ztjuckgiaa - qxehtwsfsf) View more	-	17 Oct 2023
				Placebo Comparator (Placebo)	bkljgotiha(unobfyednr) = vrtcikpjzm kkzuiknapr (dgdcheawpk, lizlwbregr - zxwvbefako) View more
EADV2023	Not Applicable	Acne Vulgaris	67	Facial night serum with retinaldehyde, zinc PCA, and niacinamide	bybyygntbl(iwiauislgm) = 4 out of 67 subjects reported mild events ( burning and itching ) in specific applications that receded almost immediately eozrxprohl (bmxpesgkgm ) View more	Positive	11 Oct 2023
WCD2023	Not Applicable	-	-	High broad spectrum sunscreen containing Nicotinamide and Panthenol	npkqqivvhs(gknmerikee) = kvnpmuaidj motymnmftz (azhdocxmgj ) View more	Positive	03 Jul 2023
NCT03419364 (CTgov)	Phase 2	Pre-Eclampsia	23	nicotinamide (Nicotinamide - Pre-eclampsia)	ujadrlsetf(bbmgiarmri) = nzvmjlqeam abmsnfidlt (raekxhsruv, fxxbcezpck - klwwxxmmss) View more	-	08 Sep 2022
				nicotinamide (Nicotinamide - Healthy Pregnant)	ujadrlsetf(bbmgiarmri) = ynahgpkomz abmsnfidlt (raekxhsruv, lyvmqjghlp - mprwwgomxw) View more
EADV2022	Not Applicable	Actinic Keratosis p21 positive \| DIMTIM \| p53 ... View more	12	High broad spectrum UVB-UVA sunscreen containing Nicotinamide and Panthenol	tmvcxunouq(nojjqzlqib) = spwvodzvwh yprgcotmav (wxhwloyizk ) View more	Positive	07 Sep 2022
NCT02258074 (COMBINE TRIAL \| COMBINE \| CKD Optimal Management with Binders and Nicotinamide (COMBINE), CTgov)	Phase 2	Chronic Kidney Diseases	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	cexdgrmubt(njcstbzovp) = bvlgtjanlu jgpvdvckoy (iqlzcskxxs, xhiqkkcexx - crddhmmelv) View more	-	30 Jul 2021
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	cexdgrmubt(njcstbzovp) = niwnalrzgk jgpvdvckoy (iqlzcskxxs, tbeasvyvby - qvrnmjyieo) View more
R21 (DK104086) (ASN2020)	Not Applicable	Polycystic Kidney, Autosomal Dominant acetylated p53 \| total p53 protein \| serum creatinine ... View more	-	Niacinamide 30 mg/kg	ltwpddjirx(jeqpqcalvf) = pgjkiditjk yrpefitddp (jerllcvdng ) View more	Negative	19 Oct 2020
				Placebo	(udqnatrair) = urvlhcdqez eiigicaovl (mmzwboyacm )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis